{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:54:12Z","timestamp":1773298452626,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10633-018-9664-8","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T15:46:51Z","timestamp":1542642411000},"page":"3-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits\u2019 eyes"],"prefix":"10.1007","volume":"138","author":[{"given":"Mayara Rodrigues Brand\u00e3o","family":"De Paiva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayara Almeida","family":"Lage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carolina Andrade","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Paulo Gomes","family":"Mol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela Coelho Silva","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo De Oliveira","family":"Fulg\u00eancio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawidson A.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela","family":"Da Costa C\u00e9sar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia Lig\u00f3rio","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Silva-Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"9664_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00163549","volume":"14","author":"RB Nussenblatt","year":"1990","unstructured":"Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14:303\u2013308","journal-title":"Int Ophthalmol"},{"key":"9664_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjo.80.9.844","volume":"80","author":"MS Suttorp-Schulten","year":"1996","unstructured":"Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80:844\u2013848. \n                    https:\/\/doi.org\/10.1136\/bjo.80.9.844","journal-title":"Br J Ophthalmol"},{"key":"9664_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","volume":"111","author":"DC Gritz","year":"2004","unstructured":"Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of uveitis study. Ophthalmology 111:491\u2013500. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2003.06.014","journal-title":"Ophthalmology"},{"key":"9664_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IIO.0b013e3181d2cc6b","volume":"50","author":"NJS London","year":"2010","unstructured":"London NJS, Rathinam SR, Cunningham ET (2010) The epidemiology of uveitis in developing countries. Int Ophthalmol Clin 50:1\u201317. \n                    https:\/\/doi.org\/10.1097\/IIO.0b013e3181d2cc6b","journal-title":"Int Ophthalmol Clin"},{"key":"9664_CR5","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.ophtha.2012.05.026","volume":"119","author":"DK Hwang","year":"2012","unstructured":"Hwang DK, Chou YJ, Pu CY, Chou P (2012) Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology 119:2371\u20132376. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2012.05.026","journal-title":"Ophthalmology"},{"key":"9664_CR6","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","volume":"121","author":"O Tomkins-Netzer","year":"2014","unstructured":"Tomkins-Netzer O, Talat L, Bar A et al (2014) Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 121:2387\u20132392. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.007","journal-title":"Ophthalmology"},{"key":"9664_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1869-5760-3-64","volume":"3","author":"DS Chu","year":"2013","unstructured":"Chu DS, Johnson SJ, Mallya UG et al (2013) Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect 3:64. \n                    https:\/\/doi.org\/10.1186\/1869-5760-3-64","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"9664_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40123-014-0023-x","volume":"3","author":"C Castiblanco","year":"2014","unstructured":"Castiblanco C, Foster CS (2014) Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther 3:17\u201336. \n                    https:\/\/doi.org\/10.1007\/s40123-014-0023-x","journal-title":"Ophthalmol Ther"},{"key":"9664_CR9","doi-asserted-by":"publisher","first-page":"18778","DOI":"10.3390\/ijms160818778","volume":"16","author":"S M\u00e9rida","year":"2015","unstructured":"M\u00e9rida S, Palacios E, Navea A, Bosch-Morell F (2015) New immunosuppressive therapies in uveitis treatment. Int J Mol Sci 16:18778\u201318795. \n                    https:\/\/doi.org\/10.3390\/ijms160818778","journal-title":"Int J Mol Sci"},{"key":"9664_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/bjophthalmol-2013-304416","volume":"98","author":"T Kanda","year":"2014","unstructured":"Kanda T, Shibata M, Taguchi M et al (2014) Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol 98:932\u2013936. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304416","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"9664_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7164\/antibiotics.51.487","volume":"51","author":"GK Wong","year":"1998","unstructured":"Wong GK, Griffith S, Kojima I, Demain AL (1998) Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin. J Antibiot 51(5):487\u2013491.\u00a0\n                    https:\/\/doi.org\/10.7164\/antibiotics.51.487","journal-title":"J Antibiot"},{"key":"9664_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128\u2013135","journal-title":"Nat Med"},{"key":"9664_CR13","unstructured":"Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964\u2013972. \n                    http:\/\/www.molvis.org\/molvis\/v10\/a115\/"},{"key":"9664_CR14","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1016\/j.febslet.2008.08.005","volume":"582","author":"A Stahl","year":"2008","unstructured":"Stahl A, Paschek L, Martin G et al (2008) Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 582:3097\u20133102. \n                    https:\/\/doi.org\/10.1016\/j.febslet.2008.08.005","journal-title":"FEBS Lett"},{"key":"9664_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10847-010-9885-2","volume":"70","author":"M Abdur Rouf","year":"2011","unstructured":"Abdur Rouf M, Vural I, Bilensoy E et al (2011) Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate. J Incl Phenom Macrocycl Chem 70:167\u2013175. \n                    https:\/\/doi.org\/10.1007\/s10847-010-9885-2","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"9664_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcp.1041540103","volume":"154","author":"N Terada","year":"1993","unstructured":"Terada N, Lucas JJ, Szepesi A et al (1993) Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 154:7\u201315. \n                    https:\/\/doi.org\/10.1002\/jcp.1041540103","journal-title":"J Cell Physiol"},{"key":"9664_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00007691-200110000-00012","volume":"23","author":"KL Napoli","year":"2001","unstructured":"Napoli KL, Taylor PJ (2001) From beach to bedside: history of the development of sirolimus. Ther Drug Monit 23:559\u2013586. \n                    https:\/\/doi.org\/10.1097\/00007691-200110000-00012","journal-title":"Ther Drug Monit"},{"key":"9664_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1208\/s12249-014-0244-2","volume":"16","author":"K Cholkar","year":"2014","unstructured":"Cholkar K, Gunda S, Earla R et al (2014) Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech 16:610\u2013622. \n                    https:\/\/doi.org\/10.1208\/s12249-014-0244-2","journal-title":"AAPS PharmSciTech"},{"key":"9664_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-5173(00)00617-7","volume":"213","author":"P Simamora","year":"2001","unstructured":"Simamora P, Alvarez JM, Yalkowsky SH (2001) Solubilization of rapamycin. Int J Pharm 213:25\u201329. \n                    https:\/\/doi.org\/10.1016\/S0378-5173(00)00617-7","journal-title":"Int J Pharm"},{"issue":"Suppl B","key":"9664_CR20","doi-asserted-by":"publisher","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","volume":"22","author":"A MacDonald","year":"2000","unstructured":"MacDonald A, Scarola J, Burke JT, Zimmerman JJ (2000) Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22(Suppl B):B101\u2013B121. \n                    https:\/\/doi.org\/10.1016\/s0149-2918(00)89027-x","journal-title":"Clin Ther"},{"key":"9664_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/02713689308999487","volume":"12","author":"FG Roberge","year":"1993","unstructured":"Roberge FG, Xu D, Chan CC et al (1993) Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 12:197\u2013203. \n                    https:\/\/doi.org\/10.3109\/02713689308999487","journal-title":"Curr Eye Res"},{"key":"9664_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/bjo.2004.048199","volume":"89","author":"VA Shanmuganathan","year":"2005","unstructured":"Shanmuganathan VA (2005) The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 89:666\u2013669. \n                    https:\/\/doi.org\/10.1136\/bjo.2004.048199","journal-title":"Br J Ophthalmol"},{"key":"9664_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.4.2.4","volume":"4","author":"MA Ibrahim","year":"2015","unstructured":"Ibrahim MA, Sepah YJ, Watters A et al (2015) One-year outcomes of the save study: sirolimus as a therapeutic approach for uveitis. Transl Vis Sci Technol 4:4. \n                    https:\/\/doi.org\/10.1167\/tvst.4.2.4","journal-title":"Transl Vis Sci Technol"},{"key":"9664_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2005.02662.x","volume":"139","author":"I Perry","year":"2005","unstructured":"Perry I, Neuberger J (2005) Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol 139:2\u201310. \n                    https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02662.x","journal-title":"Clin Exp Immunol"},{"key":"9664_CR25","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1167\/iovs.05-1425","volume":"47","author":"W Shi","year":"2006","unstructured":"Shi W, Gao H, Xie L, Wang S (2006) Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Investig Ophthalmol Vis Sci 47:3339\u20133344. \n                    https:\/\/doi.org\/10.1167\/iovs.05-1425","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"9664_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2885.2008.00986.x","volume":"31","author":"LC Douglas","year":"2008","unstructured":"Douglas LC, Yi NY, Davis JL et al (2008) Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther 31:511\u2013516. \n                    https:\/\/doi.org\/10.1111\/j.1365-2885.2008.00986.x","journal-title":"J Vet Pharmacol Ther"},{"key":"9664_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.actbio.2015.06.012","volume":"24","author":"H Hou","year":"2015","unstructured":"Hou H, Nieto A, Belghith A et al (2015) A sustained intravitreal drug delivery system with remote real time monitoring capability. Acta Biomater 24:309\u2013321. \n                    https:\/\/doi.org\/10.1016\/j.actbio.2015.06.012","journal-title":"Acta Biomater"},{"key":"9664_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/jop.2011.0226","volume":"28","author":"S Mudumba","year":"2012","unstructured":"Mudumba S, Bezwada P, Takanaga H et al (2012) Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther 28:507\u2013514. \n                    https:\/\/doi.org\/10.1089\/jop.2011.0226","journal-title":"J Ocul Pharmacol Ther"},{"key":"9664_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1869-5760-3-32","volume":"3","author":"QD Nguyen","year":"2013","unstructured":"Nguyen QD, Ibrahim MA, Watters A et al (2013) Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 3:32. \n                    https:\/\/doi.org\/10.1186\/1869-5760-3-32","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"9664_CR30","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","volume":"123","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Clark WL et al (2016) Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus study Assessing double-masKed Uveitis tReAtment (SAKURA). Ophthalmology 123:2413\u20132423. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.029","journal-title":"Ophthalmology"},{"key":"9664_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40265-015-0502-y","volume":"76","author":"A Airody","year":"2016","unstructured":"Airody A, Heath G, Lightman S, Gale R (2016) Non-infectious uveitis: optimising the therapeutic response. Drugs 76:27\u201339. \n                    https:\/\/doi.org\/10.1007\/s40265-015-0502-y","journal-title":"Drugs"},{"key":"9664_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/polym3010193","volume":"3","author":"N Kuno","year":"2011","unstructured":"Kuno N, Fujii S (2011) Recent advances in ocular drug delivery systems. Polymers (Basel) 3:193\u2013221. \n                    https:\/\/doi.org\/10.3390\/polym3010193","journal-title":"Polymers (Basel)"},{"key":"9664_CR33","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1517\/17425247.2014.935338","volume":"11","author":"JJ Kang-Mieler","year":"2014","unstructured":"Kang-Mieler JJ, Osswald CR, Mieler WF (2014) Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opin Drug Deliv 11:1647\u20131660. \n                    https:\/\/doi.org\/10.1517\/17425247.2014.935338","journal-title":"Expert Opin Drug Deliv"},{"key":"9664_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1590\/S1984-82502010000300024","volume":"46","author":"R Silva da","year":"2010","unstructured":"da Silva R, Fialho SL, Siqueira RC et al (2010) Implants as drug delivery devices for the treatment of eye diseases. Braz J Pharm Sci 46:585\u2013595. \n                    https:\/\/doi.org\/10.1590\/S1984-82502010000300024","journal-title":"Braz J Pharm Sci"},{"key":"9664_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/02713680600719036","volume":"31","author":"SL Fialho","year":"2006","unstructured":"Fialho SL, R\u00eago MB, Siqueira RC et al (2006) Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res 31:525\u2013534. \n                    https:\/\/doi.org\/10.1080\/02713680600719036","journal-title":"Curr Eye Res"},{"issue":"5391","key":"9664_CR36","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","volume":"282","author":"JA Thomson","year":"1998","unstructured":"Thomson JA, Itzkovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145\u20131147. \n                    https:\/\/doi.org\/10.1126\/science.282.5391.1145","journal-title":"Science"},{"key":"9664_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/clo.2004.6.217","volume":"6","author":"I Klimanskaya","year":"2004","unstructured":"Klimanskaya I, Hipp J, Rezai KA et al (2004) Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics. Cloning Stem Cells 6:217\u2013245. \n                    https:\/\/doi.org\/10.1089\/clo.2004.6.217","journal-title":"Cloning Stem Cells"},{"key":"9664_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/exer.1996.0020","volume":"62","author":"KC Dunn","year":"1996","unstructured":"Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62:155\u2013169","journal-title":"Exp Eye Res"},{"key":"9664_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1773-2247(07)50013-4","volume":"17","author":"SL Fialho","year":"2007","unstructured":"Fialho SL, Siqueira RC, Jorge R, Silva-Cunha A (2007) Biodegradable implants for ocular delivery of anti-inflammatory drug. J Drug Deliv Sci Technol 17:93\u201397. \n                    https:\/\/doi.org\/10.1016\/S1773-2247(07)50013-4","journal-title":"J Drug Deliv Sci Technol"},{"key":"9664_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-014-9473-7","volume":"130","author":"DL McCulloch","year":"2015","unstructured":"McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1\u201312. \n                    https:\/\/doi.org\/10.1007\/s10633-014-9473-7","journal-title":"Doc Ophthalmol"},{"key":"9664_CR41","first-page":"238","volume":"4","author":"J Barar","year":"2009","unstructured":"Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y (2009) Ocular drug delivery; impact of in vitro cell culture models. J Ophthalmic Vis Res 4:238\u2013252","journal-title":"J Ophthalmic Vis Res"},{"key":"9664_CR42","unstructured":"ISO 10993-5. (2009) Biological evaluation of medical devices\u2014Part 5: tests for in vitro cytotoxicity"},{"key":"9664_CR43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jconrel.2005.10.008","volume":"110","author":"ML Forrest","year":"2006","unstructured":"Forrest ML, Won CY, Malick AW, Kwon GS (2006) In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(\u03b5-caprolactone) micelles. J Control Release 110:370\u2013377. \n                    https:\/\/doi.org\/10.1016\/j.jconrel.2005.10.008","journal-title":"J Control Release"},{"key":"9664_CR44","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/mp400362v","volume":"10","author":"I Onyesom","year":"2013","unstructured":"Onyesom I, Lamprou DA, Sygellou L et al (2013) Sirolimus encapsulated liposomes for cancer therapy: physicochemical and mechanical characterization of sirolimus distribution within liposome bilayers. Mol Pharm 10:4281\u20134293. \n                    https:\/\/doi.org\/10.1021\/mp400362v","journal-title":"Mol Pharm"},{"key":"9664_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.colsurfb.2015.02.035","volume":"128","author":"G Li","year":"2015","unstructured":"Li G, Cao L, Zhou Z et al (2015) Rapamycin loaded magnetic Fe3O4\/carboxymethylchitosan nanoparticles as tumor-targeted drug delivery system: synthesis and in vitro characterization. Colloids Surf B Biointerfaces 128:379\u2013388. \n                    https:\/\/doi.org\/10.1016\/j.colsurfb.2015.02.035","journal-title":"Colloids Surf B Biointerfaces"},{"key":"9664_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/780634","author":"J Wang","year":"2013","unstructured":"Wang J, Jiang A, Joshi M, Christoforidis J (2013) Drug delivery implants in the treatment of vitreous inflammation. Mediat Inflamm. \n                    https:\/\/doi.org\/10.1155\/2013\/780634","journal-title":"Mediat Inflamm"},{"key":"9664_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/02713683.2013.819927","volume":"39","author":"MCM Souza","year":"2014","unstructured":"Souza MCM, Fialho SL, Souza PAF et al (2014) Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity. Curr Eye Res 39:99\u2013102. \n                    https:\/\/doi.org\/10.3109\/02713683.2013.819927","journal-title":"Curr Eye Res"},{"key":"9664_CR48","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jpba.2014.08.023","volume":"102","author":"GM Fernandes-Cunha","year":"2015","unstructured":"Fernandes-Cunha GM, Gouvea DR, de Oliveira Fulg\u00eancio G et al (2015) Development of a method to quantify clindamycin in vitreous humor of rabbits\u2019 eyes by UPLC-MS\/MS: application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation. J Pharm Biomed Anal 102:346\u2013352. \n                    https:\/\/doi.org\/10.1016\/j.jpba.2014.08.023","journal-title":"J Pharm Biomed Anal"},{"key":"9664_CR49","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3109\/1061186X.2013.829074","volume":"21","author":"SL Fialho","year":"2013","unstructured":"Fialho SL, Souza PAF, de Oliveira Fulg\u00eancio G et al (2013) In vivo release and retinal safety of intravitreal implants of thalidomide in rabbit eyes and antiangiogenic effect on the chorioallantoic membrane. J Drug Target 21:837\u2013845. \n                    https:\/\/doi.org\/10.3109\/1061186X.2013.829074","journal-title":"J Drug Target"},{"key":"9664_CR50","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1590\/S0004-27492003000700029","volume":"66","author":"SL Fialho","year":"2003","unstructured":"Fialho SL, Rego MGB, Cardillo JA et al (2003) Implantes biodegrad\u00e1veis destinados \u00e0 administra\u00e7\u00e3o intra-ocular. Arq Bras Oftalmol 66:891\u2013896. \n                    https:\/\/doi.org\/10.1590\/S0004-27492003000700029","journal-title":"Arq Bras Oftalmol"},{"key":"9664_CR51","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118:2453\u20132460. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.014","journal-title":"Ophthalmology"},{"key":"9664_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000448057","volume":"236","author":"A Klamann","year":"2017","unstructured":"Klamann A, B\u00f6ttcher K, Ackermann P et al (2017) Intravitreal dexamethasone implant for the treatment of postoperative macular edema. Ophthalmologica 236:181\u2013185. \n                    https:\/\/doi.org\/10.1159\/000448057","journal-title":"Ophthalmologica"},{"key":"9664_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/jop.2006.0083","volume":"23","author":"M Kivilcim","year":"2007","unstructured":"Kivilcim M, Peyman GA, Kazi AA et al (2007) Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther 23:57\u201362. \n                    https:\/\/doi.org\/10.1089\/jop.2006.0083","journal-title":"J Ocul Pharmacol Ther"},{"key":"9664_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.02.006","author":"T Peters","year":"2017","unstructured":"Peters T, Kim S-W, Castro V et al (2017) Evaluation of polyesteramide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats. Biomaterials. \n                    https:\/\/doi.org\/10.1016\/j.biomaterials.2017.02.006","journal-title":"Biomaterials"},{"key":"9664_CR55","doi-asserted-by":"publisher","first-page":"931","DOI":"10.6061\/clinics\/2012(08)13","volume":"67","author":"FM Damico","year":"2012","unstructured":"Damico FM, Scolari MR, Ioshimoto GL et al (2012) Vitreous pharmacokinetics and electroretinographic findings after intravitreal injection of acyclovir in rabbits. Clinics (Sao Paulo) 67:931\u2013937. \n                    https:\/\/doi.org\/10.6061\/Clinics\/2012(08)13","journal-title":"Clinics (Sao Paulo)"},{"key":"9664_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-016-9553-y","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol. \n                    https:\/\/doi.org\/10.1007\/s10633-016-9553-y","journal-title":"Doc Ophthalmol"},{"key":"9664_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/S0004-27492009000100004","volume":"72","author":"RPDA Manzano","year":"2009","unstructured":"Manzano RPDA, Peyman GA, Khan P et al (2009) Testing intravitreal toxicity of rapamycin in rabbit eyes. Arq Bras Oftalmol 72:18\u201322. \n                    https:\/\/doi.org\/10.1590\/S0004-27492009000100004","journal-title":"Arq Bras Oftalmol"},{"key":"9664_CR58","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1167\/iovs.14-15997","volume":"56","author":"A Nieto","year":"2015","unstructured":"Nieto A, Hou H, Moon SW et al (2015) Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin. Investig Ophthalmol Vis Sci 56:1070\u20131080. \n                    https:\/\/doi.org\/10.1167\/iovs.14-15997","journal-title":"Investig Ophthalmol Vis Sci"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10633-018-9664-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-018-9664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-018-9664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T11:02:43Z","timestamp":1576666963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10633-018-9664-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["9664"],"URL":"https:\/\/doi.org\/10.1007\/s10633-018-9664-8","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"23 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Informed consent was not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the welfare of animals"}}]}}